Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals
Mandate

CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals

May 10, 2005

Solvay Pharmaceuticals, the Belgium based pharmaceuticals firm, has agreed to acquire NeoPharma AB, the Sweden based pharmaceuticals firm involved in development of drugs for the treatment of Parkinson's disease, from 3i Group plc, the UK based private equity firm, and CapMan, the Finnish private equity firm, in a transaction, for approximately SEK 640m (EUR 71.26m).

Vinge acted for the sellers, being private investors as well as private equity funds including 3i and CapMan.
Anders Åberg, Malin Ohlin Åkermark (reponsible partners)
Maja Wettergren, Ola Sandersson (associates)

Related

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

 Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

 Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026

Vinge advises Stendörren in connection with issuance of green capital securities

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026